DAFNA Capital Management LLC lifted its position in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 562.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,500 shares of the company's stock after purchasing an additional 43,725 shares during the quarter. DAFNA Capital Management LLC owned about 0.35% of Neurogene worth $1,177,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in Neurogene during the third quarter worth about $324,000. Barclays PLC grew its holdings in Neurogene by 319.4% during the third quarter. Barclays PLC now owns 14,859 shares of the company's stock worth $623,000 after acquiring an additional 11,316 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Neurogene during the fourth quarter worth about $72,000. Rhumbline Advisers grew its holdings in Neurogene by 9.2% during the fourth quarter. Rhumbline Advisers now owns 15,704 shares of the company's stock worth $359,000 after acquiring an additional 1,326 shares during the period. Finally, M&T Bank Corp acquired a new stake in Neurogene during the fourth quarter worth about $323,000. 52.37% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
NGNE has been the topic of several research analyst reports. Robert W. Baird set a $38.00 price objective on Neurogene in a report on Tuesday, March 25th. BMO Capital Markets dropped their price objective on Neurogene from $45.00 to $16.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. William Blair restated an "outperform" rating on shares of Neurogene in a research report on Tuesday, March 25th. Finally, HC Wainwright decreased their target price on Neurogene from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Neurogene currently has a consensus rating of "Buy" and a consensus price target of $46.20.
Check Out Our Latest Stock Report on NGNE
Insider Buying and Selling at Neurogene
In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares in the company, valued at approximately $1,225,490.42. This trade represents a 5.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.64% of the stock is owned by insiders.
Neurogene Trading Down 10.5%
Shares of Neurogene stock traded down $1.86 during trading on Tuesday, reaching $15.84. The company's stock had a trading volume of 76,427 shares, compared to its average volume of 236,751. The company has a 50-day moving average price of $13.50 and a two-hundred day moving average price of $21.09. The firm has a market cap of $225.91 million, a PE ratio of -3.64 and a beta of 1.56. Neurogene Inc. has a fifty-two week low of $6.88 and a fifty-two week high of $74.49.
Neurogene (NASDAQ:NGNE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.03). On average, analysts predict that Neurogene Inc. will post -4.27 earnings per share for the current fiscal year.
Neurogene Profile
(
Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Further Reading
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
